TargetBeta
PGR
progesterone receptor · also PR, NR3C3 · Nuclear receptor subfamily 3 group C
6 programs in company-led studies act on PGR, from 6 companies: 1 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Megestrol Acetaterule | Changchun GeneScience Pharmaceutical | phase 4 | 198 running | – | ChEMBL |
| Levonorgestrelrule | Bayer | phase 4 | 563 running | – | ChEMBL |
| drospirenonerule | Estetra | phase 4 | 202 running | NR3C2 | ChEMBL |
| Medroxyprogesterone Acetaterule | Pfizer | phase 4 | 111 running | – | ChEMBL |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 42 running | AR, NR3C1 | ChEMBL |
| Utrogestanrule | Calla Lily Clinical Care | phase 1 | 11 running | – | ChEMBL |
Conditions their studies are in
- Adenocarcinoma, 2 programs
- Hot Flashes, 2 programs
- Neoplasms, 2 programs
- Acne Vulgaris, 1 program
- Anorexia, 1 program
- Bone Diseases, Metabolic, 1 program
- Cachexia, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Contraception Behavior, 1 program
- Diabetes Mellitus, Type 2, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026Megestrol Acetate · Changchun GeneScience Pharmaceutical · phase 4 · NCT07243379
- Dec 31, 2026Utrogestan · Calla Lily Clinical Care · phase 1 · NCT07136922
- Feb 2027Cyproterone Acetate · Eurofarma Laboratorios · phase 3 · NCT06905210
- May 31, 2027Levonorgestrel · Bayer · phase 4 · NCT07794150
- Nov 4, 2027Medroxyprogesterone Acetate · Pfizer · phase 4 · NCT06979596
- Dec 2027drospirenone · Estetra · phase 4 · NCT05303636
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.